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radiopharmaceuticalsAbstract The aim of study was to evaluate the effectiveness of 99mTc-MIBI (hexakis 2-
methoxyisobutyl isonitrile) scintigraphy to differentiate malignant from benign lesions, detected
on 99mTc-MDP planar bone scans. 59 patients with bony lesions were studied prospectively and
compared with histopathology. Each patient underwent a 99mTc-MDP scan, and if evidence of
lesion found, patient underwent 99mTc-MIBI scintigraphy after three to four days. 99mTc-MIBI
scans were evaluated visually and quantitatively. For quantitative analysis count ratio of lesion
to contralateral normal side (L/C) was taken and Student T test was applied.
99mTc-MDP scans showed increase tracer uptake but no signiﬁcant difference between benign and
malignant uptake was seen. Signiﬁcant difference (p value 0.015), was seen in malignant (L/C 3.51
± 1.02) and benign lesions (L/C 2.50 ± 0.42) on 99mTc-MIBI scan. Three of thirty benign lesions
did not show signiﬁcant 99mTc-MIBI uptake. Six malignant lesions appeared as false negatives.
Speciﬁcity of 99mTc-MIBI was 86.66%, Negative Predictive Value (NPV) 81.25% whereas the
sensitivity was 79.31%.
99mTc-MIBI scintigraphy provides its usefulness by distinguishing malignant from benign lesions
along with correct identiﬁcation of metastatic lesions. NPV points toward its ability to correctly
diagnose the normal (benign) cases. However biopsy still remains the gold standard and a deﬁnitive
diagnostic modality.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
The development and research of new imaging modalities in
musculoskeletal tumors has led to a cascade of analytical tech-
niques improving the potential for noninvasive study of the
musculoskeletal system. There are ﬁve major roles of imaging
Table 1 Visual grouping of lesions according to the intensity
of 99mTc-MIBI uptake.
Negative Lesions having no tracer uptake
Mild Faint or barely perceptible tracer uptake than the
surrounding
Moderate Well deﬁned, focal increased tracer uptake than the
surroundings
Severe Diﬀuse intense increased tracer uptake
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to differentiate between benignity and malignancy, to evaluate
for local tumor extension, to screen for metastases, to judge
the effect of chemotherapy, and to monitor for recurrence.
To accomplish this, multiple modalities are required because
no single examination is able to complete all these tasks. These
modalities include plain radiography, Computed Tomography
(CT), Magnet resonance Imaging (MRI), conventional nuclear
medicine as well as Positron Emission Tomography (PET)
imaging. For more than 30 years bone scintigraphy has been
known as one of the most sensitive noninvasive methods to
detect bone pathology. Because of its widespread availability,
moderate cost and extensive clinical experience bone scan is
still ﬁrmly established in the diagnostic algorithm to detect
or characterize lesions of all kinds, however it lacks speciﬁcity
(1). So it is difﬁcult to report a lesion as benign or malignant.
The use of speciﬁc radiopharmaceuticals permits cost effective
imaging and contributes to the preoperative differentiation.
99mTc-MIBI was originally introduced for myocardial
perfusion studies (2). In the previous decade, its noncardiac
applications such as visualization of benign and malignant
lesions in the lung (3,4), mediastinal and pulmonary metastasis
from thyroid cancer (5), astrocytoma (6), and undifferentiated
mesenchymal tumor (7) were of great value. 99mTc-MIBI is a
lipophilic cation which is predominantly stored in subcellular
structures in response to electrical potentials. Malignant cells
maintain a more negative potential secondary to increased
metabolic requirements that could promote increased accumu-
lation in malignant cells (8).
This study shows the role of 99mTc-MIBI to its full extent in
preoperative differentiation of benign versus malignant lesions
of bone. The requirement of this study arises due to the
variations in uptake ratios of 99mTc-MIBI in this geographical
location which may be due to the difference in nature of
tumors, their level of differentiation and heterogeneity. There-
fore evaluation of a range for 99mTc-MIBI uptake ratios (in
our region) will help the upcoming cases in differentiation
between benign and malignant. After the establishment of
99mTc-MIBI as a tumor imaging and differentiating agent its
application can be helpful with the diagnostic algorithm in
our centers.
2. Materials and methods
Patients presenting from September 2011 to March 2012 were
studied prospectively, 59 patients (24 males, 35 females, age
range 3–70 years; mean age, 28 ± 16 years). 48 patients with
clinical or radiologic features of primary musculoskeletal
tumors and 11 patients with suspected bone metastases were
included, a patient having any trauma or fracture noted on
X-ray was excluded. Informed consent was obtained from
every patient and study was approved by the ethical committee
of the institution. All patients were examined before biopsy,
and none had received radiotherapy or chemotherapy before
imaging.
2.1. Imaging protocol
2.1.1. 99mTc-MDP scan
After intravenous administration of 20 mCi of 99mTc-MDP
three phase bone scanning of the lesion area was performed.In cases of children under 12 years Webster rule was followed
for dose calculation,
Dose ðmCiÞ ¼ Adult dose ðmCiÞ
 ðage in yearsþ 1Þ=ðage in yearsþ 7Þð9Þ:
After the ﬂow phase (2-s images for 90s), static images were
taken 3 h later. Whole-body bone scans were also obtained for
each patient to assess tumor spread.
2.1.2. 99mTc-MIBI scan
Three to ﬁve days later of 99mTc-MDP scan 20 mCi of
99mTc-MIBI was injected intravenously and after 30 min of
tracer administration, spot views acquired over the pathologic
area (as localized by MDP scan) on a 256  256 matrix for
10 min.
All scans were done using a dual head Inﬁnia Gamma Cam-
era with a parallel hole low energy general purpose collimator
(LEGP).
2.2. Image interpretation
Each patient ﬁrst underwent a 99mTc-MDP scan which was
used as a guide to lesion localization followed by
99mTc-MIBI scan. 3 experienced nuclear physicians blind to
the radiologic ﬁndings and clinical data analyzed the bone
scans visually, each working independently. Only those lesions
were considered for 99mTc-MIBI scan which showed their
deﬁnitive presence on 99mTc-MDP scan analysis.
2.3. Data analysis
2.3.1. Qualitative (visual) assessment of 99mTc-MIBI scans
The lesions were categorized on basis of the radiotracer uptake
in accordance with the surroundings. All the lesions on
99mTc-MIBI scan were categorized in 4 groups as shown in
Table 1.
Lesions with negative and mild radiotracer uptake were
categorized as benign and lesions with moderate and severe
radiotracer uptake were placed in the malignant category.
2.3.2. Quantitative analysis on basis of uptake ratios of
99mTc-MIBI
This method was employed for the quantitation of uptake of
radiotracer in the lesion and contralateral/adjacent normal
areas to augment the visual assessment. After 30 min of tracer
administration in 99mTc-MIBI scans a Region of Interest
(ROI) was drawn around the lesion and by the help of a com-
puter generated program a exactly similar ROI was drawn on
the contralateral side automatically. Whenever contralateral
side could not be taken (as in case of spine), ROI was drawn
A/B= 2.48 
ROI A= 59.9 
ROI B= 23.35 
A B
Fig. 1 24 years old female patient with Giant cell Tumor (A) 99mTc-MDP scan showing increased tracer uptake involving the ﬁrst
metacarpal, (B) 99mTc-MIBI scan showing an ovoid area of increased tracer uptake over the ﬁrst metacarpal of right hand, L/C calculated
to be 2.48 therefore categorizing lesion as benign. (the ROI around the lesion is colored red and the ROI of contralateral normal side is
colored green).
Table 2 Number and diagnosis of benign and malignant
lesions in the study.
Benign Malignant
Diagnosis Number Diagnosis Number
Giant cell tumor 12 Ewing sarcoma 9
Osteomyelitis 4 Ca Breast mets
(appendicular)
5
Bone cyst 4 Rhabdomyosarcoma 2
Anurysmal bone
cyst
3 Osteogenic sarcoma 2
Fibrous dysplasia 2 Prostrate mets (axial) 2
Exostosis 2 Malignant nerve sheath
tumor
1
Osteoid osteoma 1 Chondroblastic
osteosarcoma
1
Enchondroma 1 Ewing mets (axial) 1
Chondroblastoma 1 NHL mets axial 1
Renal cell ca mets (axial) 1
Leukemia 1
Synovial sarcoma 1
Malignant ﬁbrous
histiocytoma
1
Renal cell Ca mets
(appendicular)
1
Total 30 29
Table 3 Visual categorization of lesions on 99mTc-MIBI scans
(n= 59).
Categorization on basis of 99mTc-
MIBI uptake
Number of
lesions (%)
Inference
Negative 3 (5%) Benign
Mild 28 (47%)
Moderate 10 (17%) Malignant
Severe 18 (30%)
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(L/C) was calculated as shown in Fig. 1.
2.4. Statistical analysis
Histopathology of lesion was considered as the gold standard.
Findings of 99mTc-MIBI scan were compared to the results of
biopsy, and lesions were categorized as true positive and false
positives.
Statistical analysis was performed by the help of SPSS-13
software, and sensitivity, speciﬁcity, positive and negative
predictive values as well as the accuracy of the diagnostic test
were calculated. Chi-square test was applied to determine the
signiﬁcance of 99mTc-MIBI to distinguish between benign
and malignant lesions visually while Independent t test was
applied for quantitative analysis.
3. Results
59 patients (24 M, 35 F) were studied prospectively. The
patient’s age ranged from, 3 to 70 years; mean age, 28
± 16 years. 30 benign and 29 malignant case (48 primary
and 11 metastatic) lesions were evaluated. The individual
lesions as classiﬁed by histopathology are given in Table 2.
3.1. Visual analysis
Twenty out of 30 proven benign and 19/29 proven malignant
lesions were correctly identiﬁed by 99mTc-MIBI on visual
assessment. All lesions were conﬁrmed by histopathology.
Negative and mild groups were considered as benign and
moderate and severe cases were grouped into malignant
category as shown in Table 3. Chi Square test was applied,
and the p value calculated was 0.03 (<0.05 is signiﬁcant), with
Df (degree of freedom) = 1.
Therefore visual assessment for differentiation between
malignant and benign lesions on 99mTc-MIBI scan was found
to be statistically signiﬁcant.
3.2. Quantitative analysis
L/C uptake ratios were calculated for all the lesions on
99mTc-MIBI scan. The mean of all the uptake ratios of
99mTc-MIBI was calculated and was maintained as the cutoffpoint. The mean uptake ratio calculated was 2.77 ± 0.86.
The lesions having no or less uptake than the mean uptake
ratios were designated as benign lesions while the lesions hav-
ing higher uptake than the mean uptake ratio were designated
as malignant.
Table 4 The results and number of patients underwent
99mTc-MIBI scintigraphy.
Results No. of patients
True positive for malignant tumor 23
True negative for malignant tumor 26
False positive 4
False negative 6
Total 59
Table 5 Quantitative result keeping histopathology of bone
biopsy as gold standard.
Sensitivity 79.31%
Speciﬁcity 86.66%
NPV 81.25%
PPV 85.18%
Accuracy 83.05%
270 A. Jabeen et al.The distribution of lesions into benign and malignant cate-
gories showed that benign lesions were 51% (30 out of 59) and
malignant lesions constituted of 48% (29 out of 59) lesions.
3.2.1. 99mTc-MIBI scanning for benign lesions
99mTc-MIBI uptake ratios in benign tumors ranged from [0 to
5.34] (Fig. 1). The average uptake ratio calculated for benign
tumors was 2.50 ± 0.42 (p value 0.015). 4/30 benign lesions
detected by 99mTc-MIBI on quantitation showed false positive
results among them were 2 Osteoid Osteomas (mean L/C ratio
3.53) and two cases of Chondroblastoma (mean L/C ratio
3.35) while two cases of Exostosis showed no 99mTc-MIBI
tracer uptake.
3.2.2. 99mTc-MIBI scanning of malignant lesions
Twenty-three out of 29 histologically proven malignant tumors
showed increased MIBI uptake. 99mTc-MIBI uptake ratios in
malignant tumors ranged from [0.84 to 10.27] (Fig. 2). The
average uptake ratio calculated for malignant tumors was
3.51 ± 1.02 (p value 0.015). 06 lesions showed decrease MIBI
uptake which included Ewing’s Sarcoma, Malignant nerve
sheath tumor, metastasis from prostate Ca (2) and Ewing’s
sarcoma categorized as false negatives.
Mean uptake ratios calculated for more than one cases of
the similar pathology showed, the highest uptake ratio in syn-
ovial sarcoma (10.06) followed by osteogenic sarcoma (6.27),
rhabdomyosarcoma (4.125), Ewing’s sarcoma (2.98), breast
cancer metastasis in appendicular skeleton.
3.3. Statistical analysis
Independent T test was applied and a highly signiﬁcant
difference was found between the L/C of benign and L/C of
malignant tumors (p< 0.005).
t value 3.150 with degree of freedom= 57. The mean
uptake of the two groups was 2.77 ± 0.86.
The performance parameters were calculated for 59
patients as tabulated in Table 4. 99mTc-MIBI scan wasA
Fig. 2 45 years old male patient of Osteosarcoma of right distal femu
the distal part of right femur (B) 99mTc-MIBI scan showing an area of i
5.29 therefore categorizing lesion as malignant (the ROI around the le
green).83.05% accurate in differentiation of malignant tumors from
benign lesions and all results are shown in Table 5.
Mean uptake ratio of the two groups is 2.77 ± 0.86. Most
uptake ratios of malignant tumors are greater than mean,
whereas most uptake ratios of benign lesions are less than
mean. The comparison of malignant and benign uptake ratios
is shown in Fig. 3. The uptake ratios of malignant tumors are
ranging from 0.8 to 10.27, with the major ratios lying between
2 and 4, whereas the range of uptake ratios of benign lesion is
from 0 to 5.34 and major ratios falling between 2 and 2.62.
4. Discussion
Various radiopharmaceuticals have been proposed as bone
tumor imaging agents. X-rays, CT, MRI, nuclear medicine
as well as PET imaging are used in diagnostic algorithm allB
ROIA=51.9 ROIB=14.1 
A/B=5.29 
r (A) 99mTc-MDP scan showing increased tracer uptake involving
ncreased tracer uptake over distal part of right femur with a L/C of
sion in colored as red and the ROI of contralateral side is colored
02
4
6
8
10
12
malignantbenign
Group
L/C count 
ratio 
Fig. 3 Comparison between 99mTc-MIBI ratios of malignant
and benign lesions. Box and whisker graph demonstrates the
comparison between the ratios of malignant and benign lesions
and the boundary closest to zero indicates the 25th percentile and
boundary farthest from zero indicates the 75th percentile.
Whiskers indicate the outliers lying at the 10th and 90th
percentiles.
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to determine whether the process is multifocal. It is of low
speciﬁcity because it does not discriminate between benign
and malignant lesions although highly sensitive. It is also not
possible to distinguish a healing process from other active
metabolic processes, such as tumor recurrence or metastases.
As the diagnosis of bone lesions is very crucial and requires
prompt diagnosis, so accurate differentiation between benign
and malignant lesions is of paramount importance (10).
99mTc-MDP skeletal scintigraphy is among the imaging tech-
niques employed for evaluation of bony lesions. The high sen-
sitivity correlates with a lower speciﬁcity because many benign
conditions, such as degenerative joint disease, infections, and
benign bone tumors, exhibit increased uptake of radiotracer,
and if lesion is solitary reliable differentiation cannot be
achieved. Biopsy still remains the gold standard in the deﬁni-
tive diagnosis, but it is subject to error and consequent compli-
cations, and also in cases of benign lesions the patient
undergoes under an unnecessary procedure. These problems
led to the research of a new technique which could effectively
distinguish between benign and malignant lesions.
Bone tumor imaging agents such as 67Gallium are popular,
but poor physical characteristics, long waiting periods, and its
lack of speciﬁcity are disadvantages (11). 201Thallium has been
proposed to be a sensitive radiopharmaceutical for detection of
bone sarcoma and evaluation of response to therapy. Yet its
long biologic half-life limits the administered dose, frequently
resulting in long imaging times. Therefore use of these radio-
pharmaceuticals with the passage of time is diminishing with
the advent of new radiopharmaceuticals appropriate in all
aspects. 99mTc-MIBI is a well known myocardial perfusion
agent (12). Following the inadvertent discovery of the uptake
of 99mTc-MIBI in a lung cancer by Delmon Moingeon et al.
in 1990, led to its evolvement as a tumor imaging agent due
to its uptake in various human cell lines (13). The distributionof 99mTc-MIBI in vivo is not only a simple function of blood
ﬂow, but also represents metabolic function. The uptake of
99mTc-MIBI apart from blood ﬂow depends upon the cell via-
bility, metabolic conditions, and its retention mechanism
(5,7,14). It also has the ability to differentiate post therapeutic
necrosis from residual viable tumor tissue or local recurrence,
therefore clearly over riding the CT and MRI in detection of
viability of tumor. This is achieved by both qualitative and
retention mechanisms of 99mTc-MIBI, which depends on mito-
chondria and negative membrane potential (15). 99mTc has a
shorter physical half-life of 6 h which permits the use of a
higher administered dose as compared to 201Tl, which trans-
lates to a higher count rate which will shorten imaging times
and provide clear and better resolution images. The gamma
energy of 99mTc (140 keV) is optimal for use with the detector
crystal used in the gamma camera and will undergo less atten-
uation and scatter. Aktolun et al. (16) compared the differ-
ences in 99mTc-MIBI and 201Tl uptake in 17 patients with
known malignancy mainly breast and lung cancers and the
uptake ratios were found to be similar, except for 1 patient
of breast cancer which was only localized by 99mTc-MIBI.
Another study conducted on brain tumors showed that
both the radiotracers showed uptake in tumor cells but 6 of
the cases showed increased lesion to normal side ratio for
99mTc-MIBI (6). Taking into consideration these studies it
can be depicted that the tumor cell lines are clearly localized
by both 99mTc-MIBI and 201Thallium but due to the favorable
characteristics, sufﬁcient dose can be given in 99mTc-MIBI for
radionuclide angiography, and hence blood pool studies can
also play a role in assessment and localization of tumor with
99mTc-MIBI which cannot be done with Thallium.
99mTc-MIBI provides better localization and categorization
of bone and soft tissue lesions into benign and malignant cat-
egories as compared to other imaging modalities. A study con-
ducted by Moustafa et al. (17) showed 6 false positives among
24 adequately controlled bone and soft tissue tumors which
were falsely diagnosed by CT/MRI as positive recurrent tumor
which were not evident on MIBI scan and biopsy. The sensitiv-
ity, speciﬁcity, and accuracy of 99mTc-MIBI in detection of
bone, soft tissue tumors were 93%, 95%, and 92% as com-
pared to CT, MRI which were 86%, 75% and 84%,
respectively.
There are studies in which 99mTc-MIBI uptake ratios were
compared with 99mTc-MDP. Caner et al. also reported that,
the extent of the pathology seen on 99mTc-MDP images was
generally larger and showed greater uptake ratios than that
on the corresponding 99mTc-MIBI images. This was thought
to be due to the assumption that 99mTc-MDP uptake is a
reﬂection of both bone blood ﬂow and osteoblastic activity,
while 99mTc-MIBI is taken up by the tumor cells, whether it
is bone or soft tissue. In patients with extensive uptake pattern
with 99mTc-MIBI, the soft-tissue component of the tumor in
addition to bone involvement was detected histologically (7).
In our study that was conducted to differentiate malignant
from benign lesions, there were a total of 59 lesions, in which
there were 29 malignant lesions of which 11 were metastatic
bone lesions. The objective of our study was to categorize
the lesions noted on 99mTc-MDP as benign or malignant on
the basis of 99mTc-MIBI scan.
On qualitative (visual) analysis the lesions were signiﬁcantly
differentiated 20/30 and 19/29 lesions were correctly identiﬁed.
Benign lesions showed increased 99mTc-MIBI uptake and then
Table 6 Comparison of 99mTc-MIBI uptake ratios with
previous studies.
Serial number Study name Benign Malignant
1 Pinkas et al. 1.22 ± 0.43 2.25 ± 1.03
2 Caner et al. 1.26 ± 0.40 2.21 ± 1.17
3 Taki et al. 1.82 ± 1.11 2.01 ± 0.99
4 Present study 2.5 ± 0.42 3.51 ± 1.02
272 A. Jabeen et al.the criteria for benign lesions visually included cases of giant
cell tumor and chondroblastoma. This may be due to the
increase in vascularity and high level of metabolic activity of
the cells, whereas the metastatic lesions located in the axial
skeleton and some cases of Ewing’s sarcoma showed decreased
99mTc-MIBI uptake. The groups were statistically analyzed
and the result was signiﬁcant. Therefore, enabling the worth
of 99mTc-MIBI in visual assessment (p value 0.03).
On quantitative analysis 22/29 (76%) lesions showed
increased tracer uptake and 7 lesions (24%) showed less tracer
uptake than the mean uptake ratio calculated for malignant
tumors. 23/30 (77%) benign lesions showed less tracer uptake.
3 (10%) benign lesions showed no tracer uptake while 4 lesions
(13%) showed increased tracer uptake than the mean uptake
ratio calculated for benign tumors. The mean uptake ratio
calculated for the two groups was 2.77 ± 0.86. The quantita-
tive analysis was more signiﬁcant than the visual analysis (p
0.015 and 0.03 respectively). Therefore 23 cases were true pos-
itives for malignant tumors and 26 were true negatives. The
test was 79.31% sensitive, 86.66% speciﬁc with a negative pre-
dictive value (NPV) of 81.25% and 83.05% accurate (Table 5)
as compared with Pinkas et al. which was 87% speciﬁc and
81% sensitive.
Most malignant tumors (22/29) showed increased tracer
uptake with a mean L/C ratio of 3.51 ± 1.02. The uptake
ratios of malignant tumors were noted to be higher than the
mean uptake ratio of both groups. These results compared
to results by Pinkas et al. (18) show better differentiation
between malignant and benign lesions. Metabolism, necrosis
and some other factors might cause these uptake differences.
The highest L/C was found to be of synovial sarcoma which
was signiﬁcantly higher than the uptake ratios in other tumors.
In a similar study conducted by Rodriguez et al. (19) with dif-
ferent radiopharmaceuticals in different soft tissue sarcomas,
synovial sarcoma was seen to have highest uptake ratio.
Differences in metabolic capacity between cell types may thus
account for the heterogeneity of uptake seen in synovial
sarcoma and other malignant tumors.
The intensity of uptake in Ewing’s sarcoma was quite vari-
able and ranged from 1.19 to 4.16. The mean uptake ratio of
Ewing Sarcoma was 3.02 ± 0.84. In this study it was noted
that out of 9 cases of Ewing’s Sarcoma 1 case showed
decreased tracer uptake than the mean uptake ratio, while 3
cases showed borderline uptake while 5 cases showed high
uptake ratios. Similar results were also appreciated in the study
conducted by Caner et al. (20). Recent studies show that an
osseous equivalent of a malignant, small cell neoplasm of neu-
ral crest origin apparently exists within the bones (Askin’s
tumor) and its differentiation from Ewing’s sarcoma is difﬁcult
(21,22). The tumors diagnosed as Ewing’s sarcoma that
showed mild tracer uptake on the 99mTc-MIBI images might
be such newly described tumors originating from the neural
crest. A detailed histopathological evaluation and immunohis-
tochemistry are needed to differentiate between Ewing’s Sar-
coma and Askin’s tumor. Thus it shows that uptake of MIBI
not only depends on the tumor type but also on its level of dif-
ferentiation, metabolism, blood supply, viability and level of
necrosis.
Similar studies carried out over the period of time for dif-
ferentiating malignancies from benign lesions, have yielded
similar results as seen in Zhi-yun et al. (23), however the ratios
of benign and malignant tumors are different owing to thedifference in geographical location, tumor grade, level of dif-
ferentiation of tumors and grade of heterogeneity. The sum-
mary of studies in comparison with our study in summarized
in Table 6.
23 of 30 (79%) benign tumors showed 99mTc-MIBI uptake.
While 3 benign tumors showed no uptake on 99mTc-MIBI
scan, 2 of these lesions were conﬁrmed as bone cyst and 1
lesion was found out to be exostosis. Osteomyelitis (L/C
5.34) shows the highest uptake followed by giant cell tumor
(L/C 4.73) and osteoid osteoma (L/C 3.53) making as false
positive.
Giant cell tumor (GCT) showed increased tracer uptake
than the mean uptake ratio, similar results are seen in the stud-
ies conducted by Pinkas et al. (18) and Taki et al. (24), GCT is
a heterogeneous tumor composed of three different cell popu-
lations. The giant-cell tumor stromal cells (GCTSC) constitute
the neoplastic cells, the mononuclear histiocytic cells (MNHC)
and multinucleated giant cell (MNGC) fractions are secondar-
ily recruited and comprise the non-neoplastic cell population.
The GCTSC lineage is responsible for the increase in tracer
uptake and false positive result on 99mTc-MIBI scans (25).
99mTc-MIBI detects lesions located in the axial skeleton as
seen in study by Wakasugi et al. (26), but it poses difﬁculty in
differentiating of lesions usually located in the axial skeleton.
Lesions located axially are not clearly differentiated due to
the masking of activity of the gut and heart. Due to this reason
99mTc-MIBI poses difﬁculty when lesions are placed in ster-
num or spine, the activity of the heart and gut as higher in
counts masks the activity seen in the lesion and hence the
lesion is not localized.
Newer modalities are being used for detection of muscu-
loskeletal tumors one of them is FDG-PET. Tumor imaging
with FDG is based on the hypothesis that the rate of anaerobic
glycolysis increases with differentiation of tumor cells and with
an increasing grade of malignancy. Several different neoplasms
have been imaged with FDG since the ﬁrst demonstration of
its ability to localize cerebral gliomas (27). PET imaging of
musculoskeletal masses does have certain pitfalls given its lim-
ited resolution. There must also be some concern about the
natural variability of FDG accumulation in benign or malig-
nant processes, since numerous factors (i.e., blood ﬂow,
plasma glucose concentration and tissue hexokinase activities)
in addition to glucose metabolic rate determine FDG accumu-
lation and the nonavailability and high cost of the test limits its
usefulness. FDG-PET and 99mTc-MIBI-SPECT are useful
adjunct tools in the evaluation of musculoskeletal tumors, par-
ticularly in distinguishing between benign and malignant tissue
components (28). If there is clinical or histological evidence of
recurrence but the 99mTc-MIBI-SPECT is negative, a more
expensive FDG-PET scan is recommended to investigate pos-
sible drug-resistance. Therefore 99mTc-MIBI is cost effective,
99mTc-MIBI Scintigraphy to differentiate malignancies from benign lesions 273sensitive and provides good evaluation and differentiation of
lesions.
99mTc-MIBI plays an important role in imaging of non-
speciﬁc lesion detected on bone scans; it provides precise local-
ization, deﬁnes the morphological signiﬁcance and improves
the speciﬁcity of planar bone scan. The results of our study
showed that MIBI improves the accuracy of diagnosis of a
lesion as benign or malignant.
5. Conclusion
This study suggests that 99mTc-MIBI scintigraphy plays an
important role to distinguish malignancies from benign lesions
which are detected on planar bone scan with good sensitivity
and high speciﬁcity. Its high PPV renders it a good diagnostic
option for differentiation of lesions. Biopsy still remains the
deﬁnitive diagnostic modality but 99mTc-MIBI provides clue
to the diagnosis and can help in preventing unnecessary inter-
vention in benign lesions. 99mTc-MIBI provides better results
when analyzed quantitatively as compared to visual
assessment.
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